| P50 | author | Roger S McIntyre | Q88039086 |
| | Susan L McElroy | Q56816544 |
| P2093 | author name string | Ross A Baker | |
| | Robert A Forbes | |
| | James M Eudicone | |
| | Berit X Carlson | |
| P2860 | cites work | Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization | Q80000044 |
| | Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists | Q80359248 |
| | Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). | Q31147616 |
| | Excess mortality in bipolar and unipolar disorder in Sweden | Q33954560 |
| | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 |
| | Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 |
| | Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. | Q35631515 |
| | Are mood disorders and obesity related? A review for the mental health professional. | Q35783981 |
| | Medical risk in patients with bipolar disorder and schizophrenia. | Q36590638 |
| | Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review | Q36771704 |
| | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. | Q37171035 |
| | Bipolar disorder and metabolic syndrome: an international perspective | Q37764504 |
| | Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 |
| | Use of Clinical Markers to Identify Metabolic Syndrome in Antipsychotic-Treated Patients | Q38497882 |
| | Treatment with antipsychotics and the risk of diabetes in clinical practice | Q42872475 |
| | Metabolic syndrome in patients with bipolar disorder | Q43859298 |
| | Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. | Q43892160 |
| | Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. | Q43997748 |
| | Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 |
| | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. | Q44167467 |
| | Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 |
| | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 |
| | Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. | Q44662788 |
| | A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole | Q44845645 |
| | Hyperlipidemia following treatment with antipsychotic medications. | Q45934694 |
| | The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. | Q45969182 |
| | Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 |
| | A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia | Q46262718 |
| | Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 |
| | Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder | Q46756223 |
| | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 |
| | A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 |
| | Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder | Q47331378 |
| | Naturalistic impact of second-generation antipsychotics on weight gain | Q47344131 |
| | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder | Q47345706 |
| | The effects of hypertension and body mass index on cognition in schizophrenia. | Q51045058 |
| | Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. | Q51487290 |
| | Obesity among those with mental disorders: a National Institute of Mental Health meeting report. | Q51839698 |
| P433 | issue | 6 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | The primary care companion for CNS disorders | Q26853834 |
| P1476 | title | A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder | |
| P478 | volume | 13 | |